H.C. Wainwright lowered the firm’s price target on Celldex (CLDX) to $42 from $50 and keeps a Buy rating on the shares. The company announced mixed topline results from its Phase 2 trial assessing barzolvolimab in eosinophilic esophagitis, the analyst tells investors in a research note. The firm removing eosinophilic esophagitis from its barzolvolimab projected indications.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex price target lowered to $38 from $44 at Wells Fargo
- Celldex’s Promising Pipeline and Financial Stability Justify Buy Rating Despite Recent Setback
- Closing Bell Movers: La-Z-Boy down 24% after earnings miss
- Celldex down 12.5% at $21.01 after barzolvolimab study update
- Celldex Halts Barzolvolimab Development for EoE